Cell and Gene Champions Speak Up
Get a sharp perspective on the cell and gene status quo in The Medicine Maker 2022 supplement on advanced medicine
Angus Stewart | | Opinion
sponsored by Bio-Rad, Eppendorf, Millipore Sigma, OmniaBio, and Thermo Fisher Scientific
This year, our cell and gene supplement takes a close look at the state of the field, and the problems that it is facing. In the main feature, we draw on the expert takes sent to us throughout 2022 by various cell and gene “Champions” – opinion leaders and innovators observing, researching, and trying to commercialize cutting edge cell and gene therapies. Our champions includeBruce Levine (University of Pennsylvania), Chelsea Pratt (Bio-Rad), Dave Seaward (3P innovation), Miguel Forte (BioSenic), and more. Also included in the supplement:
- Lentiviral vs adeno-associated – the pros and cons of vector properties
- How more efficient manufacturing can help meet rare disease needs
- Nineties nostalgia with a major player from gene therapy’s early days
- Reaching beyond the lower branches of possible ophthalmic treatments
- And more!
Itching to dive in? Download the PDF.